776 Of Patients Achieved Primary Multi Endpoint In Pathway China Trial

Palopegteriparatide Shows Promise for Treating Chronic Kidney Disease-Mineral Bone Disorder

77.6% of Patients Achieved Primary Multi-Endpoint in PaTHway China Trial

VISTEN Pharmaceuticals Announces Post Hoc Analysis Results

Shanghai, China - August 12, 2024 - VISEN Pharmaceuticals, an innovative biopharmaceutical company, today announced the results of a post hoc analysis of the PaTHway China Trial, evaluating the efficacy of palopegteriparatide in treating chronic kidney disease-mineral bone disorder (CKD-MBD).

Palopegteriparatide is a synthetic analog of parathyroid hormone (PTH), which plays a crucial role in calcium and bone metabolism. The PaTHway China Trial enrolled 343 patients with CKD-MBD and treated them with either palopegteriparatide or placebo for 12 months.

The primary multi-endpoint of the trial was to achieve independence from active vitamin D, independence from therapeutic doses of calcium, and normalization of serum calcium and phosphate levels. The results showed that 77.6% of patients treated with palopegteriparatide achieved the primary multi-endpoint, compared to 14.7% of patients treated with placebo.

Conclusion:

The results of this post hoc analysis provide further evidence of the efficacy of palopegteriparatide in treating CKD-MBD. Palopegteriparatide has the potential to significantly improve the quality of life for patients with CKD-MBD by reducing their dependence on medications and improving their bone health.